Tender detail
Conclusion of non-exclusive pharmaceutical discount agreements for certolizumab pegol under an open-house model
Summary
The procurement concerns non-exclusive pharmaceutical discount agreements for medicines containing the active substance certolizumab pegol (WHO ATC code L04AB05), concluded under an open-house model. The quantity is unknown and no minimum purchase volume is guaranteed. Agreements end no later than 31 October 2027.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.